SITE010-0039

SITE010 (ESP) › SITE010-0039

SITE010-0039

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE010 (ESP) · Dr. Silva
consented 2025-10-12

enrolled

AEs

4

Serious

0

Dropout signal

–

Adverse events

4

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-12-10 (study day 232); relationship: not assessed

mild assessed

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-11-17 (study day 209); relationship: not assessed

mild assessed

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-06-01 (study day 40); relationship: RELATED

moderate assessed

Grade 1 Pruritus — outcome: RECOVERED/RESOLVED; onset 2022-05-21 (study day 29); relationship: RELATED

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.